Combined SCLC clinical and pathological aspects
Filiz Çimen1, Sevim Düzgün2, Sükran Atikcan3
1Department of Pulmonary Medicine, Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Health Sciences University, Ankara. fhcimen@yahoo.com.
Abstract:
Combined small cell lung carcinoma (C-SCLC) is rare and accounts for 1-3% of all lung cancer cases. Although its incidence has increased recently, there are limited studies on it. The records of patients admitted to our hospital between January 2015 and December 2019 and diagnosed with histologically proven combined small cell were scanned retrospectively and reviewed. 31 patients were analyzed. The average follow-up time was 10 months. The radiotherapy (RT) rate, surgery rate, and large cell malignancy rate were significantly lower in the ex group than in the living group (p=0.024, p=0.023, p=0.015). The rates of extensive disease, metastasis, and thyroid transcription factor 1 (TTF1) were significantly higher in the old group than in the living group (p=0.000, p=0.000, p=0.029, respectively). In the univariate model, sequential RT, fatigue, lactate dehydrogenase (LDH), stage, metastasis, contralateral lung metastasis, chemotherapy were observed to be significantly effective in predicting survival time (p=0.000, p=0.050, p=0.011, p=0.004, p=0.004, p=0.045, p=0.009). In the multivariate model, independent (p=0.015, p=0.022, p=0.049) efficacy of RT, stage, and chemotherapy in predicting survival was observed. C-SCLC is a specific mixed carcinoma and reports evaluating this type are still scarce. The stage of the disease, radiotherapy and chemotherapy are extremely important in predicting survival.
Insights
Combined small cell lung carcinoma (C-SCLC) is a rare lung cancer. Radiotherapy, chemotherapy, and disease stage are crucial for predicting survival in C-SCLC patients.
Area of Science:
- Oncology
- Pulmonology
- Medical Research
Background:
- Combined small cell lung carcinoma (C-SCLC) is a rare subtype, comprising 1-3% of all lung cancers.
- Despite a recent increase in incidence, research on C-SCLC remains limited.
- This study focuses on understanding the prognostic factors in C-SCLC.
Purpose of the Study:
- To retrospectively analyze patient data to identify factors influencing survival in C-SCLC.
- To evaluate the efficacy of treatments like radiotherapy and chemotherapy.
- To determine the significance of disease stage and metastasis in patient outcomes.
Main Methods:
- Retrospective review of 31 patients diagnosed with histologically proven C-SCLC between January 2015 and December 2019.
- Analysis of patient records including treatment rates (radiotherapy, surgery), disease characteristics (stage, metastasis), and biomarkers (TTF1, LDH).
- Univariate and multivariate statistical models were used to identify predictors of survival time.
Main Results:
- Lower rates of radiotherapy, surgery, and large cell malignancy were observed in the non-surviving group.
- Higher rates of extensive disease, metastasis, and TTF1 expression were noted in the non-surviving group.
- Radiotherapy, chemotherapy, and disease stage were independently significant predictors of survival in the multivariate analysis.
Conclusions:
- C-SCLC is a distinct entity requiring further investigation due to its rarity.
- Disease stage, radiotherapy, and chemotherapy are critical factors for predicting survival in C-SCLC.
- Effective treatment strategies incorporating radiotherapy and chemotherapy are essential for improving outcomes in C-SCLC patients.
More Related Videos
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
07:43Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
